Pfizer and French biotech company Valneva are launching a clinical trial to test the only current vaccine candidate against Lyme disease, the companies announced Monday.
Why it matters: The study could result in the first possible vaccine against the disease in two decades. Almost half a million people may get Lyme disease in the U.S. each year, according to the CDC.
